Display options
Cite
Wu Y, He F, Li Y, et al. Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats. Evid Based Complement Alternat Med. 2017;2017:7674240doi: 10.1155/2017/7674240.
Wu, Y., He, F., Li, Y., Wang, H., Shi, L., Wan, Q., Ou, J., Zhang, X., Huang, D., Xu, L., Lin, P., Yang, G., He, L., & Gao, J. (2017). Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats. Evidence-based complementary and alternative medicine : eCAM, 20177674240. https://doi.org/10.1155/2017/7674240
Wu, Yansheng, et al. "Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats." Evidence-based complementary and alternative medicine : eCAM vol. 2017 (2017): 7674240. doi: https://doi.org/10.1155/2017/7674240
Wu Y, He F, Li Y, Wang H, Shi L, Wan Q, Ou J, Zhang X, Huang D, Xu L, Lin P, Yang G, He L, Gao J. Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats. Evid Based Complement Alternat Med. 2017;2017:7674240. doi: 10.1155/2017/7674240. Epub 2017 Nov 12. PMID: 29358971; PMCID: PMC5735790.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2017;2017:7674240. doi: 10.1155/2017/7674240. Epub 2017 Nov 12.

Effects of Shizhifang on NLRP3 Inflammasome Activation and Renal Tubular Injury in Hyperuricemic Rats.

Evidence-based complementary and alternative medicine : eCAM

Yansheng Wu, Fei He, Yingqiao Li, Huiling Wang, Liqiang Shi, Qiang Wan, Jiaoying Ou, Xiaoying Zhang, Di Huang, Lin Xu, Pinglan Lin, Guanghui Yang, Liqun He, Jiandong Gao

Affiliations

  1. Department of Nephrology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, TCM Institute of Kidney Disease of Shanghai University of Traditional Chinese Medicine, Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, No. 528 Zhangheng Road, Shanghai 201203, China.
  2. Department of Nephrology, Xiamen Hospital of Traditional Chinese Medicine, No. 1739 Xianyue Road, Xiamen 361009, China.
  3. Department of Nephrology, Traditional Chinese Medicine Hospital of Langfang City, No. 108 North Yinhe Road, Langfang 065000, China.
  4. Department of Internal Medicine, Shanghai TCM-Integrated Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 184 Baoding Road, Shanghai 200082, China.
  5. Department of Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Shanghai 201203, China.
  6. Department of Rheumatology and Immunology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, No. 528 Zhangheng Road, Shanghai 201203, China.

PMID: 29358971 PMCID: PMC5735790 DOI: 10.1155/2017/7674240

Abstract

OBJECTIVE: Uric acid (UA) activates the NLRP3-ASC-caspase-1 axis and triggers cascade inflammatory that leads to hyperuricemic nephropathy and hyperuricemia-induced renal tubular injury. The original study aims to verify the positive effects of the traditional Chinese medicinal formula Shizhifang (SZF) on ameliorating the hyperuricemia, tubular injury, and inflammasome infiltration in the kidneys of hyperuricemic lab rats.

METHOD: Twenty-eight male Sprague-Dawley rats were divided into four groups: control group, oxonic acid potassium (OA) model group, OA + SZF group, and OA + Allopurinol group. We evaluated the mediating effects of SZF on renal mitochondrial reactive oxygen species (ROS) and oxidative stress (OS) products, protein expression of NLRP3-ASC-caspase-1 axis, and downstream inflammatory factors IL-1

RESULT: SZF alleviated OA-induced hyperuricemia and inhibited OS in hyperuricemic rats (

CONCLUSION: Our data suggest that SZF alleviates renal tubular injury and inflammation infiltration by inhibiting NLRP3 inflammasome activation triggered by mitochondrial ROS in the kidneys of hyperuricemic lab rats.

References

  1. Nat Commun. 2015 Mar 24;6:6555 - PubMed
  2. PLoS One. 2015 Feb 13;10(2):e0117516 - PubMed
  3. PLoS One. 2012;7(10):e47299 - PubMed
  4. Front Immunol. 2014 Jan 09;4:514 - PubMed
  5. Nature. 2011 Jan 13;469(7329):221-5 - PubMed
  6. Clin Chem Lab Med. 2016 Jan;54(1):7-15 - PubMed
  7. Eur J Pharmacol. 2015 Jan 15;747:59-70 - PubMed
  8. Cell. 2014 May 22;157(5):1013-22 - PubMed
  9. PLoS One. 2012;7(6):e38285 - PubMed
  10. Toxicol Lett. 2016 Mar 30;246:7-16 - PubMed
  11. J Urol. 2015 May;193(5):1684-91 - PubMed
  12. J Nutr Biochem. 2014 Mar;25(3):353-62 - PubMed
  13. Nature. 2006 Mar 9;440(7081):237-41 - PubMed
  14. Ther Adv Musculoskelet Dis. 2015 Dec;7(6):225-33 - PubMed
  15. Nature. 2015 Oct 29;526(7575):666-71 - PubMed
  16. Biochem Biophys Res Commun. 2014 May 16;447(4):707-14 - PubMed
  17. EMBO J. 2016 Aug 15;35(16):1766-78 - PubMed
  18. Antioxid Redox Signal. 2015 Apr 1;22(10 ):848-70 - PubMed
  19. Sci Rep. 2015 Oct 22;5:15489 - PubMed
  20. Hypertension. 2001 Nov;38(5):1101-6 - PubMed
  21. Can J Diabetes. 2015 Jun;39(3):239-46 - PubMed
  22. Nat Rev Rheumatol. 2013 Jan;9(1):13-23 - PubMed
  23. Am J Physiol Renal Physiol. 2013 Mar 1;304(5):F471-80 - PubMed
  24. Am J Physiol Renal Physiol. 2014 Jan 1;306(1):F75-84 - PubMed
  25. Oxid Med Cell Longev. 2015;2015:535686 - PubMed
  26. J Med Assoc Thai. 2010 Nov;93 Suppl 6:S65-70 - PubMed
  27. Nature. 2015 Oct 29;526(7575):660-5 - PubMed
  28. Nephrol Dial Transplant. 2016 Jun;31(6):890-6 - PubMed
  29. J Rheumatol. 2001 Jul;28(7):1640-6 - PubMed
  30. J Med Genet. 2010 Mar;47(3):204-10 - PubMed
  31. Nature. 2015 Oct 29;526(7575):642-3 - PubMed
  32. Int J Mol Med. 2015 May;35(5):1347-54 - PubMed
  33. Adv Chronic Kidney Dis. 2012 Nov;19(6):419-24 - PubMed
  34. Redox Biol. 2015 ;4:296-307 - PubMed
  35. Eur Rev Med Pharmacol Sci. 2015 Feb;19(4):640-6 - PubMed
  36. Pediatr Nephrol. 2016 Apr;31(4):535-44 - PubMed

Publication Types